TALi Digital (ASX:TD1) is a small digital health and education-technology company that has just asked shareholders to back a change of direction: buying Datasphere Analytics, which holds an option over in-memory computing technology. The option has a deadline of 3 October 2026, so the next few days matter more than usual.

Existing business

TALi sells digital programmes aimed at cognitive and wellbeing outcomes, including its YCDI! platform used for teacher wellbeing. Its latest quarterly report, published on 30 July 2026 for the June quarter, put cash at A$1.0 million and Revenue cash inflows at A$105,000 for the quarter. The company said operating cash burn remained low and consistent with guidance. Those figures show a Business with modest recurring income and a limited cash cushion before the new raising.

The same report described a Victorian Resilient Educator Partnership: a 14-month agreement running from August 2026 to October 2027 covering about 250 schools. The initial phase involves at least 60 teachers, with potential to expand beyond 400. The company said potential revenue could exceed A$0.5 million. That is a potential figure under an announced agreement; it is not revenue recognised in the accounts.

The Datasphere deal

On 24 August 2026 TALi announced it would acquire 100% of Datasphere Analytics for 22 million shares at A$0.05 each. Datasphere holds an exclusive option to license memristive in-memory computing intellectual property from the Technion Research and Development Foundation. The technology processes analytics inside memory arrays rather than moving data to a separate processor, which the company suggests could speed analysis of large datasets. That is a description of the intended benefit, not proven performance.

The option can be exercised until 3 October 2026 and requires qualifying financing of US$650,000. Acquiring an option is not the same as owning commercial technology, and the path from licence to product is long and uncertain.

The raising

TALi launched a A$3.3 million raising at A$0.05 per share: a A$2.8 million Placement in two tranches and a share purchase plan of up to A$500,000. Investors receive one free option for every three shares, exercisable at A$0.15 with a five-year expiry. The company’s stated use of funds was A$920,000 for the qualifying financing payment, A$580,000 for technology Due Diligence and commercialisation, A$650,000 for existing product development, A$550,000 for staffing and marketing, and A$600,000 for Working Capital and costs.

Shareholders approved all ten resolutions at an extraordinary general meeting on 25 September 2026, with approval rates between about 99% and 99.97%. Directors took part in the placement and share purchase plan. The company’s timetable had the Acquisition completing and the second Tranche settling on 29 September 2026.

Sector context

Healthcare-technology businesses often grow slowly through institutional sales cycles, while deep-technology licensing involves research risk. Combining the two within a company with about A$1 million of pre-raising cash increases execution risk, and the raising dilutes existing holders.

What to watch

Confirmation of completion, whether the Technion option is exercised by 3 October 2026, and the September-quarter cash report.